AI-supported development of universal personalized TCR immunotherapies against cancer
CompanyTcelltech GmbH, Mannheim, Germany
Tcelltech GmbH specializes in the development and production of TCR immunotherapy technologies. In collaboration with the German Cancer Research Center (DKFZ), the company has developed the personalized adoptive cell therapy UNIPACT, which is intended to enable universal control of all types of cancer. UNIPACT is based on two different platforms. The AI-based bioinformatics platform selectTCR enables the identification of reactive T cell receptors (TCRs) that recognize and specifically target tumor cells within a few days. Because the TCRs come directly from patients, they do not cause off-target toxicity and can be immediately used to produce modified T cells. SelectTCR's proof-of-concept has been carried out in previous studies in melanoma, colon, pancreatic, lung and brain cancer. The company has developed the high-performance DNA vector platform nanoSMAR to load the patient's own T cells with the selected TCRs. nanoSMAR enables safe and efficient gene expression without damaging cells or activating the immune system. The technology allows long-term gene expression with large genetic capacity. In summary, UNIPACT proves to be a groundbreaking approach that accelerates the development of personalized cancer therapies and can help increase patients' chances of survival and reduce undesirable therapeutic side effects.
Pioneering antigen-agnostic TCR T cell therapies
info@tcelltech.de
Added on: 04-02-2024
[1] https://www.tcelltech.eu/platforms
